- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Top 5 Articles of the Week: January 5-10
Author(s):
Key Takeaways
- VYNE Therapeutics progresses with repibresib gel for vitiligo, expecting phase 2b trial results in mid-2025.
- Anti-inflammatory moisturizers improve skin hydration and barrier function in mild to moderate atopic dermatitis.
Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
1. VYNE Completes Phase 2b Enrollment for Vitiligo Gel
VYNE Therapeutics announced this week the completion of enrollment in a phase 2b trial of repibresib (VYN201) gel for nonsegmental vitiligo. This milestone marks significant progress in developing a potential treatment for this autoimmune depigmenting disorder, with top-line results areanticipated in mid-2025.
2. The Impact of Anti-Inflammatory Moisturizers in Mild to Moderate Atopic Dermatitis Treatment
In patients with mild to moderate atopic dermatitis, moisturizers with anti-inflammatory ingredients improved skin hydration even further than those without, according to a recent study. Although clinical improvement was seen in both variations, anti-inflammatory moisturizers further improved skin hydration and barrier function while reducing inflammatory lesions in patients.
3. FDA Proposes Mandatory Asbestos Testing for Talc-Containing Cosmetics
In a recent move to protect consumers, the US Food and Drug Administration announced a proposed rule mandating standardized testing methods for detecting and identifyingasbestos in talc-containing cosmetic products. This proposal aims to safeguard public health by addressing the potential risks of asbestos contamination in products that often come into direct contact with the skin.
4. The Relationships Between Vitamin D, Zinc, and Seborrheic Dermatitis
A case-control study conducted at Deziani Clinic, Iran, examined serum levels of vitamin D and zinc in 71 SD patients and 71 healthy controls. The study found no statistically significant difference in vitamin D levels between the groups. However, patients with moderate to severe SD exhibited lower average vitamin D levels compared to those with mild cases. Zinc levels, on the other hand, were significantly lower in patients with SD, suggesting a more robust association with the condition.
5. Ionic Liquids Boost Skin Drug Delivery
In a recent interview with Dermatology Times, Samir Mitragotri, PhD, a professor of bioengineering at Harvard University and founder of CAGE Bio, discussed advancements in ionic liquid technology and its application in dermatological therapeutics.
